Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

Bin Zhang, Natalie A. Bowerman, Joseph K. Salama, Hank Schmidt, Michael T. Spiotto, Andrea Schietinger, Ping Yu, Yang Xin Fu, Ralph R. Weichselbaum, Donald A. Rowley, David M. Kranz, Hans Schreiber

Research output: Contribution to journalArticle

Abstract

Targeting cancer cells, as well as the nonmalignant stromal cells cross-presenting the tumor antigen (Ag), can lead to the complete destruction of well-established solid tumors by adoptively transferred Ag-specific cytotoxic T lymphocytes (CTLs). If, however, cancer cells express only low levels of the Ag, then stromal cells are not destroyed, and the tumor escapes as Ag loss variants. We show that treating well-established tumors expressing low levels of Ag with local irradiation or a chemotherapeutic drug causes sufficient release of Ag to sensitize stromal cells for destruction by CTLs. This was shown directly using high affinity T cell receptor tetramers for visualizing the transient appearance of tumor-specific peptide-MHC complexes on stromal cells. Maximum loading of tumor stroma with cancer Ag occurred 2 d after treatment and coincided with the optimal time for T cell transfer. Under these conditions, tumor rejection was complete. These findings may set the stage for developing rational clinical protocols for combining irradiation or chemotherapy with CTL therapy. JEM

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalJournal of Experimental Medicine
Volume204
Issue number1
DOIs
StatePublished - Jan 22 2007

Fingerprint

T-Lymphocytes
Stromal Cells
Antigens
Neoplasms
Cytotoxic T-Lymphocytes
Tumor Escape
Neoplasm Antigens
Clinical Protocols
T-Cell Antigen Receptor
Drug Therapy
Peptides
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., ... Schreiber, H. (2007). Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. Journal of Experimental Medicine, 204(1), 49-55. https://doi.org/10.1084/jem.20062056

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. / Zhang, Bin; Bowerman, Natalie A.; Salama, Joseph K.; Schmidt, Hank; Spiotto, Michael T.; Schietinger, Andrea; Yu, Ping; Fu, Yang Xin; Weichselbaum, Ralph R.; Rowley, Donald A.; Kranz, David M.; Schreiber, Hans.

In: Journal of Experimental Medicine, Vol. 204, No. 1, 22.01.2007, p. 49-55.

Research output: Contribution to journalArticle

Zhang, B, Bowerman, NA, Salama, JK, Schmidt, H, Spiotto, MT, Schietinger, A, Yu, P, Fu, YX, Weichselbaum, RR, Rowley, DA, Kranz, DM & Schreiber, H 2007, 'Induced sensitization of tumor stroma leads to eradication of established cancer by T cells', Journal of Experimental Medicine, vol. 204, no. 1, pp. 49-55. https://doi.org/10.1084/jem.20062056
Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. Journal of Experimental Medicine. 2007 Jan 22;204(1):49-55. https://doi.org/10.1084/jem.20062056
Zhang, Bin ; Bowerman, Natalie A. ; Salama, Joseph K. ; Schmidt, Hank ; Spiotto, Michael T. ; Schietinger, Andrea ; Yu, Ping ; Fu, Yang Xin ; Weichselbaum, Ralph R. ; Rowley, Donald A. ; Kranz, David M. ; Schreiber, Hans. / Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. In: Journal of Experimental Medicine. 2007 ; Vol. 204, No. 1. pp. 49-55.
@article{3fb2597b8ba6453cb15d3b20a819a16b,
title = "Induced sensitization of tumor stroma leads to eradication of established cancer by T cells",
abstract = "Targeting cancer cells, as well as the nonmalignant stromal cells cross-presenting the tumor antigen (Ag), can lead to the complete destruction of well-established solid tumors by adoptively transferred Ag-specific cytotoxic T lymphocytes (CTLs). If, however, cancer cells express only low levels of the Ag, then stromal cells are not destroyed, and the tumor escapes as Ag loss variants. We show that treating well-established tumors expressing low levels of Ag with local irradiation or a chemotherapeutic drug causes sufficient release of Ag to sensitize stromal cells for destruction by CTLs. This was shown directly using high affinity T cell receptor tetramers for visualizing the transient appearance of tumor-specific peptide-MHC complexes on stromal cells. Maximum loading of tumor stroma with cancer Ag occurred 2 d after treatment and coincided with the optimal time for T cell transfer. Under these conditions, tumor rejection was complete. These findings may set the stage for developing rational clinical protocols for combining irradiation or chemotherapy with CTL therapy. JEM",
author = "Bin Zhang and Bowerman, {Natalie A.} and Salama, {Joseph K.} and Hank Schmidt and Spiotto, {Michael T.} and Andrea Schietinger and Ping Yu and Fu, {Yang Xin} and Weichselbaum, {Ralph R.} and Rowley, {Donald A.} and Kranz, {David M.} and Hans Schreiber",
year = "2007",
month = "1",
day = "22",
doi = "10.1084/jem.20062056",
language = "English (US)",
volume = "204",
pages = "49--55",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "1",

}

TY - JOUR

T1 - Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

AU - Zhang, Bin

AU - Bowerman, Natalie A.

AU - Salama, Joseph K.

AU - Schmidt, Hank

AU - Spiotto, Michael T.

AU - Schietinger, Andrea

AU - Yu, Ping

AU - Fu, Yang Xin

AU - Weichselbaum, Ralph R.

AU - Rowley, Donald A.

AU - Kranz, David M.

AU - Schreiber, Hans

PY - 2007/1/22

Y1 - 2007/1/22

N2 - Targeting cancer cells, as well as the nonmalignant stromal cells cross-presenting the tumor antigen (Ag), can lead to the complete destruction of well-established solid tumors by adoptively transferred Ag-specific cytotoxic T lymphocytes (CTLs). If, however, cancer cells express only low levels of the Ag, then stromal cells are not destroyed, and the tumor escapes as Ag loss variants. We show that treating well-established tumors expressing low levels of Ag with local irradiation or a chemotherapeutic drug causes sufficient release of Ag to sensitize stromal cells for destruction by CTLs. This was shown directly using high affinity T cell receptor tetramers for visualizing the transient appearance of tumor-specific peptide-MHC complexes on stromal cells. Maximum loading of tumor stroma with cancer Ag occurred 2 d after treatment and coincided with the optimal time for T cell transfer. Under these conditions, tumor rejection was complete. These findings may set the stage for developing rational clinical protocols for combining irradiation or chemotherapy with CTL therapy. JEM

AB - Targeting cancer cells, as well as the nonmalignant stromal cells cross-presenting the tumor antigen (Ag), can lead to the complete destruction of well-established solid tumors by adoptively transferred Ag-specific cytotoxic T lymphocytes (CTLs). If, however, cancer cells express only low levels of the Ag, then stromal cells are not destroyed, and the tumor escapes as Ag loss variants. We show that treating well-established tumors expressing low levels of Ag with local irradiation or a chemotherapeutic drug causes sufficient release of Ag to sensitize stromal cells for destruction by CTLs. This was shown directly using high affinity T cell receptor tetramers for visualizing the transient appearance of tumor-specific peptide-MHC complexes on stromal cells. Maximum loading of tumor stroma with cancer Ag occurred 2 d after treatment and coincided with the optimal time for T cell transfer. Under these conditions, tumor rejection was complete. These findings may set the stage for developing rational clinical protocols for combining irradiation or chemotherapy with CTL therapy. JEM

UR - http://www.scopus.com/inward/record.url?scp=33846429184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846429184&partnerID=8YFLogxK

U2 - 10.1084/jem.20062056

DO - 10.1084/jem.20062056

M3 - Article

C2 - 17210731

AN - SCOPUS:33846429184

VL - 204

SP - 49

EP - 55

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 1

ER -